Effect of high doses of erythropoietin on its antiapoptotic function on differentiated erythroid cells

MALTANERI, ROMINA; VITTORI, DANIELA; CHAMORRO, M. EUGENIA; SCHIAPPACASSE, AGUSTINA; NESSE, ALCIRA

Mar del Plata

Congreso; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2019

Sociedad Argentina de Investigación Clínica

Recombinant human erythropoietin (Epo) has been successful in the treatment of anemia of different etiologies but high Epo doses, used to reduce the frequency of administration or to treat refractory anemia, have been linked with adverse outcomes. Previously, we observed a decreased effect of high Epo concentrations on endothelial cell migration. Here, we studied the antiapoptotic effect of Epo on erythroleukemia K562 cells exposed to TNF-α (T), after incubation with increasing concentrations of Epo (10, 100 and 400 U/mL) and erythroid differentiation with hemin. While Epo10 prevented the increase in the percentage of apoptotic nuclei observed with TNF-α, Epo100 and Epo400 did not show that protection.Considering that this effect could be related to the decreased availability of the Epo receptor, we investigated the activity of protein tyrosine phosphatase 1B (PTP1B) and the process of proteasomal degradation in this cell model. PTP1B activity, which regulates many aspects of the signaling pathways elicited by Epo upon EpoR activation, showed no significant differences between cultures with low and high Epo concentrations. Then, we used the proteasome inhibitor MG132 to evaluate if EpoR internalization could affect the antiapoptotic effect of Epo against TNF-α. In the presence of MG132, the results with high concentrations of Epo were similar to those observed with Epo10T (Hoechst staining, C 13.5±0.7%, T 31.5±1.5%*, Epo10T 22.1±1.1%*, Epo100T 29.4±1.4%*, Epo400T 29.9±2.2%*, Epo100TMG 21.7±19%, Epo400TMG 22±1.3%, *P